Skip to Content

Ranibizumab ophthalmic Disease Interactions

There are 2 disease interactions with ranibizumab ophthalmic:


Intravitreal Injections (Includes Ranibizumab ophthalmic) ↔ Ocular Infections

Severe Potential Hazard, High plausibility

Applies to: Ocular Infection, Uveitis, Orbital Infection, Infectious Endophthalmitis, Infectious Optic Neuritis

Intravitreal administration, including those with aflibercept, pegaptanib, and ranibizumab is contraindicated in patients with active intraocular inflammation or ocular/periocular infections, since endophthalmitis can occur following the use of these injections. Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive or painful, or if there is a change in vision in the days following the injection.


Ranibizumab Intravitreal Injection (Includes Ranibizumab ophthalmic) ↔ Increased Intraocular Pressure

Moderate Potential Hazard, Moderate plausibility

Applies to: Glaucoma/Intraocular Hypertension

Increases in intraocular pressure have been reported both pre- injection and post- injection (at 60 minutes) while being treated with ranibizumab. Intraocular pressure should be monitored prior and following intravitreal injection with ranibizumab and managed appropriately.

ranibizumab ophthalmic drug Interactions

There is 1 drug interaction with ranibizumab ophthalmic

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.